Cargando…
The Medical Research Council Myeloma IX trial: the impact on treatment paradigms*
Osteolytic bone disease is a hallmark of symptomatic multiple myeloma. Bisphosphonates have been the mainstay of treatment to preserve skeletal integrity and prevent skeletal-related events in patients with myeloma-related bone disease. Recently, the MRC Myeloma IX trial demonstrated for the first t...
Autores principales: | Richardson, Paul G, Laubach, Jacob P, Schlossman, Robert L, Ghobrial, Irene M, Mitsiades, Constantine S, Rosenblatt, Jacalyn, Mahindra, Anuj, Raje, Noopur, Munshi, Nikhil, Anderson, Kenneth C |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3267050/ https://www.ncbi.nlm.nih.gov/pubmed/21991938 http://dx.doi.org/10.1111/j.1600-0609.2011.01721.x |
Ejemplares similares
-
The Treatment of Multiple Myeloma Patients Not Eligible for Asct
por: Richardson, Paul, et al.
Publicado: (2010) -
Lenalidomide in multiple myeloma: an evidence-based review of its role in therapy
por: Richardson, Paul, et al.
Publicado: (2010) -
Bortezomib in the management of multiple myeloma
por: Laubach, Jacob P, et al.
Publicado: (2009) -
Phase 1 open-label study of panobinostat, lenalidomide, bortezomib + dexamethasone in relapsed and relapsed/refractory multiple myeloma
por: Laubach, Jacob P., et al.
Publicado: (2021) -
Quality of life, psychological distress, and prognostic perceptions in caregivers of patients with multiple myeloma
por: O’Donnell, Elizabeth K., et al.
Publicado: (2022)